Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Lupus and Lupus Nephritis: Improving Outcomes and Reducing Disparities
  • CME
  • CE

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Released: May 25, 2022 Expiration: May 24, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by an educational grant from
GlaxoSmithKline
Karen H. Costenbader, MD, MPH
Brad H. Rovin, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients with SLE
  • Implement LN screenings in patients with SLE
  • Summarize recent advances regarding the appropriate use of available and emerging therapies for SLE and LN
  • Detail strategies to reduce health disparities affecting patients with SLE and LN

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Karen H. Costenbader, MD, MPH

Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Lupus Program
Division of Rheumatology, Inflammation and Immunity
Brigham and Women's Hospital
Boston, Massachusetts

Karen H. Costenbader, MD, MPH, has disclosed that she has received funds for research support from Exagen, Gilead Sciences, and Merck and consulting fees from Amgen, AstraZeneca, GlaxoSmithKline, Janssen, and Lilly.
Brad H. Rovin, MD

Professor and Director, Division of Nephrology
The Lee A. Hebert Professor of Nephrology
Medical Director
, The Ohio State Center for Clinical Research Management
The Ohio State University Wexner Medical Center
Columbus, Ohio

Brad H. Rovin, MD, FASN, FACP, has disclosed that he has received funds for research support from Aurinia, BioCryst, Biogen Idec, Bristol-Myers Squibb, Calliditas, ChemoCentryx, Human Genome Sciences, Idorsia, and Lucin and consulting fees from Admirx, Alexion, AstraZeneca, Aurinia, BioCryst, Biogen Idec, Bristol-Myers Squibb, Calliditas, Chugai, Corrona, EMD Serono, Genentech/Hoffmann-La Roche, Janssen, Kezar Life Sciences, Lilly, MorphoSys, Novartis, Omeros, Otsuka, Pfizer, Principia, and Travere.

Staff

Craig Borders
Vice President, Managing Scientific Director
Craig Borders has no relevant conflicts of interest to report.
Jennifer Simpson, DNP
Jennifer Simpson, DNP, has disclosed that she has received speaker fees from AbbVie and Janssen; and has served on the advisory board for Amgen and AstraZeneca.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatologists, nephrologists, primary care physicians, nurse practitioners, and other healthcare professionals who care for patients with SLE.

Goal

The goal of this initiative is to improve the knowledge and competence of learners in rheumatology and nephrology settings regarding the management of SLE and LN, including the management of patients with SLE/LN affected by health disparities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 25, 2022, through May 24, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Lupus and Lupus Nephritis: Improving Outcomes and Reducing Disparities
  • CME
  • CE

Loading...
Experts discuss recent advances in SLE and lupus nephritis, including diagnosing SLE, screening for nephritis, the latest approaches to management, and addressing disparities in care.
Karen H. Costenbader, MD, MPH
Brad H. Rovin, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Released: May 25, 2022 Expiration: May 24, 2023

Related Content

Concise microlearning module featuring expert insight on the cardiorenal benefits of SGLT2 inhibitors in T2D from Clinical Care Options (CCO)

Jennifer B. Green, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: July 12, 2022 Expired: July 11, 2023

Unlocked downloadable slides featuring an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes, from Clinical Care Options (CCO)

Jennifer B. Green, MD Released: July 12, 2022

On-demand webcast featuring an expert panel with insight on new data presented at ECCO 2022 for Crohn disease and ulcerative colitis from Clinical Care Options (CCO)

Uma Mahadevan, MD Bruce E. Sands, MD, MS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: May 19, 2022 Expired: May 18, 2023

Clinical Care Options (CCO) presents expert commentary on new data in Crohn disease and ulcerative colitis from ECCO 2022

Bruce E. Sands, MD, MS Released: May 13, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings